Evidence map›Paper›PMID 35349756›Full record

ArticleImmunity, inflammation and disease2022

Long-term SARS-CoV-2-specific and cross-reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology.

Ida Laurén, Sebastian Havervall, Henry Ng, Martin Lord, Aleksandra Pettke, Nina Greilert-Norin, Lena Gabrielsson, Aikaterini Chourlia, Catarina Amoêdo-Leite, Vijay S Josyula and 21 more

Open access · goldAbstract read
In one paragraph

Article in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 4 institutions in 1 country.

Ida LaurénDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-0041-6084
Sebastian HavervallDepartment of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Henry NgDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-2873-9088
Martin LordDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Aleksandra PettkeDepartment of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden.
Nina Greilert-NorinDepartment of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Lena GabrielssonDepartment of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Aikaterini ChourliaDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Catarina Amoêdo-LeiteDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Vijay S JosyulaDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Mohamed EltahirDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Iliana KerzeliDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
August J FalkDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.ORCID 0000-0002-7773-1851
Jonathan HoberDepartment of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Wanda ChristDepartment of Medicine Huddinge, Karolinska Institute, Centre for Infectious Medicine, Stockholm, Sweden.
Anna WibergDepartment of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
My HedhammarDivision of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Hanna TegelDivision of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Joachim BurmanDepartment of Neuroscience, Uppsala University, Uppsala, Sweden.
Feifei XuDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Elisa PinDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
Anna MånbergDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
Jonas KlingströmDepartment of Medicine Huddinge, Karolinska Institute, Centre for Infectious Medicine, Stockholm, Sweden.
Gustaf ChristofferssonDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Sophia HoberDivision of Protein Technology, Department of Protein Science, KTH Royal Institute of Technology, Stockholm, Sweden.
Peter NilssonDivision of Affinity Proteomics, Department of Protein Science, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden.
Mia PhilipsonDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Pierre DönnesSciCross AB, Skövde, Sweden.
Robin LindsayDepartment of Medical Cell Biology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Charlotte ThålinDepartment of Clinical Sciences, Karolinska Institute, Danderyd Hospital, Stockholm, Sweden.
Sara MangsboDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.ORCID 0000-0002-1355-2678
Uppsala University · SEKarolinska Institutet · SEScience for Life Laboratory · SEKTH Royal Institute of Technology · SE

Funding

Erling Persson Family FoundationHjärt-Lungfonden 20190468Jonas & Kristina af Jochnick FoundationKnut och Alice Wallenbergs Stiftelse 2020-05880Leif Lundblad Family FoundationRegion StockholmScience for Life LaboratorySvenska Sällskapet för Medicinsk ForskningVetenskapsrådet 2018-02552Vetenskapsrådet 2020-05782
6 · The paper itself

Abstract

backgroundCellular immune memory responses post coronavirus disease 2019 (COVID-19) have been difficult to assess due to the risks of contaminating the immune response readout with memory responses stemming from previous exposure to endemic coronaviruses. The work herein presents a large-scale long-term follow-up study investigating the correlation between symptomology and cellular immune responses four to five months post seroconversion based on a unique severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific peptide pool that contains no overlapping peptides with endemic human coronaviruses.

methodsPeptide stimulated memory T cell responses were assessed with dual interferon-gamma (IFNγ) and interleukin (IL)-2 Fluorospot. Serological analyses were performed using a multiplex antigen bead array.

resultsOur work demonstrates that long-term SARS-CoV-2-specific memory T cell responses feature dual IFNγ and IL-2 responses, whereas cross-reactive memory T cell responses primarily generate IFNγ in response to SARS-CoV-2 peptide stimulation. T cell responses correlated to long-term humoral immune responses. Disease severity as well as specific COVID-19 symptoms correlated with the magnitude of the SARS-CoV-2-specific memory T cell response four to five months post seroconversion.

conclusionUsing a large cohort and a SARS-CoV-2-specific peptide pool we were able to substantiate that initial disease severity and symptoms correlate with the magnitude of the SARS-CoV-2-specific memory T cell responses.

Indexed as

COVID-19SARS-CoV-2CD4-Positive T-LymphocytesFollow-Up StudiesHumansImmunity, CellularSeverity of Illness IndexB-cellIFNγIL-2SARS-Cov-2T cell

Identifiers

PMID35349756
PMCPMC8962644
OpenAlexW4220986639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.